Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Shares of Intelligent Systems INS, +0.57% have been on an absolute tear lately. Shares are up more than 150% year-to-date since Jan. 1, and more than 500% in the last year! That’s because this yet-unprofitable small-cap stock has seen equally impressive revenue growth thanks to its payment processing technology.
CoreCard is a leading issuer-processor and provider of card management and transaction processing systems. CoreCard offers an array of account management and system of record solutions to support the complex requirements of the evolving global financial services industry.
The CoreCard platform provides the market’s most feature-rich design for card processing and managing accounts. The platform supports a full range of card products including prepaid/stored-value, fleet, revolving credit, loans, pay-day lending, debit, commercial, government, healthcare and private-label cards.
Second-quarter profit rose to 44 percent by $5.98 per share price, compared with $3.95 per share. Total revenue rose around 19 percent to $9.4 billion.